Aleyna Erakcaoğlu

Ms. Aleyna Erakcaoğlu

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
MCMuhammet Cengi̇z
Muhammet Cengi̇z
ACAyse NURANSOY Cengiz
Ayse NURANSOY Cengiz
OBOKTAY BOZKURT
OKTAY BOZKURT
GZGozde Erturk Zararsiz
Gozde Erturk Zararsiz
ADAhmet Kürşad Dişli
Ahmet Kürşad Dişli
MOMetin Ozkan
Metin Ozkan
Background/objectives Patients with metastatic prostate cancer (mPC) represent a population with a higher proportion of elderly patients compared to other patient groups. Androgen receptor pathway inhibitors (ARPISs) are frequently used in current treatment regimens. Although the Prognostic Nutritional Index (PNI) is widely utilized, its stand alone capacity to accurately predict overall survival (OS) and progression-free survival (PFS) remains limited. This study aimed to evaluate the prognostic value of PNI in mPC patients treated with ARPIs and to optimize survival predictions by developing integrated multivariable logistic and Cox regression models. Methods PNI was calculated at baseline and third month after treatment initiation. To assess cross-sectional predictive capability, multivariable logistic regression models were developed for OS and PFS events, and their diagnostic performance was evaluated using Receiver Operating Characteristic (ROC) curve analysis. Subsequently, time-to-event dynamics and hazard ratios were analyzed using univariable and multivariable Cox proportional hazards regression. Results The multivariable logit model demonstrated robust predictive performance for survival outcomes. Utilizing the model-derived optimal probability cutoff of 0.343, patients were successfully stratified into distinct prognostic cohorts. The high-probability risk group (≥ 0.343, n = 86) exhibited a significantly worse prognosis, with accelerated curve decline and earlier, more frequent mortality. In contrast, the low-probability group (< 0.343, n = 51) showed a favorable prognosis, maintaining an approximate 30% survival rate up to the 75th month (Log-rank p = 0.009). Conclusion Evaluating nutrition alone is not enough to predict how mPC patients will progress. By tracking PNI changes over time and combining them into multivariable logistic model, we can much better predict overall survival and progression-free survival. In practice, using our model's 0.343 cutoff score allows us to easily catch high-risk patients early on, helping physician step in with personalized nutritional and medical support.

9 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ACAyse NURANSOY Cengiz
Ayse NURANSOY Cengiz
MCMuhammet Cengi̇z
Muhammet Cengi̇z
OBOKTAY BOZKURT
OKTAY BOZKURT
GZGozde Erturk Zararsiz
Gozde Erturk Zararsiz
AEAleyna Erakcaoğlu
Aleyna Erakcaoğlu
MOMetin Ozkan
Metin Ozkan
Background/Objectives: Therapeutic options for metastatic breast cancer vary according to hormone receptor (HR) status, human epidermal growth factor receptor 2 (HER2) status, and, importantly, the newly recognized HER2-low status. In triple-negative breast cancer (TNBC), characterized by the absence of HR and HER2 receptors, therapeutic approaches and survival rates differ significantly. Current treatments have improved survival rates in metastatic diseases, resulting in an increased demand for secondary biopsies. The findings from these biopsies affect the range of therapeutic options. Methods: The data of 172 patients with metastatic breast cancer were retrospectively analyzed. The initial and subsequent biopsy specimens from these patients were compared. Their effects on survival and prognosis were analyzed statistically. Results: Overall, 12.8% of patients transitioned to triple-negative status. Upon analysis of HER2-low status, 13.4% of patients initially classified as HER2-negative transitioned to HER2-low status. The median overall survival was 26 months (95% CI: 19.1–32.8) in the HR-concordant group and 21 months (95% CI: 14.3–27.6) in the HR-discordant group (p < 0.03). Conclusions: The present study clarifies the rates of HR and HER2 receptor concordance and discordance in metastatic breast cancer. It provides a comprehensive dataset that incorporates all receptors and TNBC transformation. Furthermore, it demonstrates conversion to HER2-low status and examines the implications of TNBC transformation and HR discordance on prognosis and survival.